The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major advancement in schizophrenia treatment in decades.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

Investigators conducted a systematic review and meta-analysis to elucidate the efficacy and safety of cTBS for the treatment of auditory hallucinations in schizophrenia.

Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...

A shorter course of post-mastectomy radiation doesn't jeopardize a patient's chances of successful breast reconstruction, a ...

Methylene blue and red light therapy are showing promise for treating depression. Read on to learn how these therapeutics may ...

Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for ...

People with schizophrenia need lifelong treatment and this includes medicine, talk therapy and help in learning how to manage daily life activities. If schizophrenia is not treated, it can lead to ...

Recent research is painting a clearer picture of the link between the use of clozapine for schizophrenia and respiratory ...

The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday.The ...

The FDA approved a new drug for schizophrenia. Discrimination is stressing Chinese Americans and damaging their mental health.

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...